nach oben

Diabetologia

Erschienen in:

11.03.2016 | MINI-Review

The role of leptin in diabetes: metabolic effects

verfasst von: Thomas H. Meek, Gregory J. Morton

Erschienen in: Diabetologia | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Abstract

While it is well established that the adiposity hormone leptin plays a key role in the regulation of energy homeostasis, growing evidence suggests that leptin is also critical for glycaemic control. In this review we examine the role of the brain in the glucose-lowering actions of leptin and the potential mediators responsible for driving hyperglycaemia in states of uncontrolled insulin-deficient diabetes (uDM). These considerations highlight the possibility of targeting leptin-sensitive pathways as a therapeutic option for the treatment of diabetes. This review summarises a presentation given at the ‘Is leptin coming back?’ symposium at the 2015 annual meeting of the EASD. It is accompanied by two other reviews on topics from this symposium (by Christoffer Clemmensen and colleagues, DOI: 10.1007/s00125-016-3906-7, and by Gerald Shulman and colleagues, DOI: 10.1007/s00125-016-3909-4) and an overview by the Session Chair, Ulf Smith (DOI: 10.1007/s00125-016-3894-7).

International Diabetes Federation (2013) IDF diabetes atlas, 6th edn. International Diabetes Federation, Brussels

Chen L, Magliano DJ, Zimmet PZ (2011) The worldwide epidemiology of type 2 diabetes mellitus—present and future perspectives. Nat Rev Endocrinol 8:228–236CrossRefPubMed

Banting FG, Best CH (1990) Pancreatic extracts. 1922. J Lab Clin Med 115:254–272PubMed

The DCCT Research Group (1988) Weight gain associated with intensive therapy in the diabetes control and complications trial. Diabetes Care 11:567–573

The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986CrossRef

The Diabetes Control and Complications Trial Research Group (1997) Hypoglycemia in the diabetes control and complications trial. Diabetes 46:271–286CrossRef

Morton GJ, Schwartz MW (2011) Leptin and the central nervous system control of glucose metabolism. Physiol Rev 91:389–411CrossRefPubMedPubMedCentral

Dubuc PU (1976) The development of obesity, hyperinsulinemia, and hyperglycemia in ob/ob mice. Metabolism 25:1567–1574CrossRefPubMed

Wyse BM, Dulin WE (1970) The influence of age and dietary conditions on diabetes in the db mouse. Diabetologia 6:268–273CrossRefPubMed

10.

Pelleymounter MA, Cullen MJ, Baker MB et al (1995) Effects of the obese gene product on body weight regulation in ob/ob mice. Science 269:540–543CrossRefPubMed

11.

Schwartz MW, Baskin DG, Bukowski TR et al (1996) Specificity of leptin action on elevated blood glucose levels and hypothalmic neuropeptide Y gene expression in ob/ob mice. Diabetes 45:531–535CrossRefPubMed

12.

Gavrilova O, Marcus-Samuels B, Leon LR, Vinson C, Reitman ML (2000) Leptin and diabetes in lipoatrophic mice. Nature 403:850, discussion 850–851PubMed

13.

Shimomura I, Hammer RE, Ikemoto S, Brown MS, Goldstein JL (1999) Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 401:73–76CrossRefPubMed

14.

Petersen KF, Oral EA, Dufour S et al (2002) Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest 109:1345–1350CrossRefPubMedPubMedCentral

15.

Patni N, Garg A (2015) Congenital generalized lipodystrophies—new insights into metabolic dysfunction. Nat Rev Endocrinol 11:522–534PubMed

16.

Chinookoswong N, Wang JL, Shi ZQ (1999) Leptin restores euglycemia and normalizes glucose turnover in insulin-deficient diabetes in the rat. Diabetes 48:1487–1492CrossRefPubMed

17.

Yu X, Park BH, Wang MY, Wang ZV, Unger RH (2008) Making insulin-deficient type 1 diabetic rodents thrive without insulin. Proc Natl Acad Sci U S A 105:14070–14075CrossRefPubMedPubMedCentral

18.

Havel PJ, Uriu-Hare JY, Liu T et al (1998) Marked and rapid decreases of circulating leptin in streptozotocin diabetic rats: reversal by insulin. Am J Physiol 274:R1482–R1491PubMed

19.

Fujikawa T, Chuang JC, Sakata I, Ramadori G, Coppari R (2010) Leptin therapy improves insulin-deficient type 1 diabetes by CNS-dependent mechanisms in mice. Proc Natl Acad Sci U S A 107:17391–17396CrossRefPubMedPubMedCentral

20.

German JP, Thaler JP, Wisse BE et al (2011) Leptin activates a novel CNS mechanism for insulin-independent normalization of severe diabetic hyperglycemia. Endocrinology 152:394–404CrossRefPubMedPubMedCentral

21.

Hidaka S, Yoshimatsu H, Kondou S et al (2002) Chronic central leptin infusion restores hyperglycemia independent of food intake and insulin level in streptozotocin-induced diabetic rats. FASEB J 16:509–518CrossRefPubMed

22.

Lin CY, Higginbotham DA, Judd RL, White BD (2002) Central leptin increases insulin sensitivity in streptozotocin-induced diabetic rats. Am J Physiol Endocrinol Metab 282:E1084–E1091CrossRefPubMed

23.

Morton GJ, Meek TH, Schwartz MW (2014) Neurobiology of food intake in health and disease. Nat Rev Neurosci 15:367–378CrossRefPubMedPubMedCentral

24.

Ahima RS, Prabakaran D, Mantxoros C et al (1996) Role of leptin in the neuroendocrine response to fasting. Nature 382:250–252CrossRefPubMed

25.

Unger RH, Cherrington AD (2012) Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. J Clin Invest 122:4–12CrossRefPubMedPubMedCentral

26.

Dobbs R, Sakurai H, Sasaki H et al (1975) Glucagon: role in the hyperglycemia of diabetes mellitus. Science 187:544–547CrossRefPubMed

27.

Muller WA, Faloona GR, Unger RH (1971) The effect of experimental insulin deficiency on glucagon secretion. J Clin Invest 50:1992–1999CrossRefPubMedPubMedCentral

28.

Gerich J, Davis J, Lorenzi M et al (1979) Hormonal mechanisms of recovery from insulin-induced hypoglycemia in man. Am J Physiol 236:E380–E385PubMed

29.

Raskin P, Unger RH (1978) Hyperglucagonemia and its suppression. N Engl J Med 299:433–436CrossRefPubMed

30.

Lee Y, Wang MY, Du XQ, Charron MJ, Unger RH (2011) Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice. Diabetes 60:391–397CrossRefPubMedPubMedCentral

31.

Lee Y, Berglund ED, Wang MY et al (2012) Metabolic manifestations of insulin deficiency do not occur without glucagon action. Proc Natl Acad Sci U S A 109:14972–14976CrossRefPubMedPubMedCentral

32.

Strack AM, Sebastian RJ, Schwartz MW, Dallman MF (1995) Glucocorticoids and insulin: reciprocal signals for energy balance. Am J Physiol 268:R142–R149PubMed

33.

Perry RJ, Zhang XM, Zhang D et al (2014) Leptin reverses diabetes by suppression of the hypothalamic–pituitary–adrenal axis. Nat Med 20:759–763CrossRefPubMedPubMedCentral

34.

Morton GJ, Meek TH, Matsen ME, Schwartz MW (2015) Evidence against hypothalamic–pituitary–adrenal axis suppression in the anti-diabetic action of leptin. J Clin Invest 125:4587–4591CrossRefPubMed

35.

Schwartz MW, Strack AM, Dallman MF (1997) Evidence that elevated plasma corticosterone levels are the cause of reduced hypothalamic corticotrophin-releasing hormone gene expression in diabetes. Regul Pept 72:105–112CrossRefPubMed

36.

German JP, Wisse BE, Thaler JP et al (2010) Leptin deficiency causes insulin resistance induced by uncontrolled diabetes. Diabetes 59:1626–1634CrossRefPubMedPubMedCentral

37.

Omar BA, Andersen B, Hald J, Raun K, Nishimura E, Ahren B (2014) Fibroblast growth factor 21 (FGF21) and glucagon-like peptide 1 contribute to diabetes resistance in glucagon receptor-deficient mice. Diabetes 63:101–110CrossRefPubMed

38.

Gelling RW, Du XQ, Dichmann DS et al (2003) Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice. Proc Natl Acad Sci U S A 100:1438–1443CrossRefPubMedPubMedCentral

39.

Meek TH, Dorfman MD, Matsen ME et al (2015) Evidence that in uncontrolled diabetes, hyperglucagonemia is required for ketosis but not for increased hepatic glucose production or hyperglycemia. Diabetes 64:2376–2387CrossRefPubMed

40.

Cryer PE (2004) Diabetes mellitus: a fundamental and clinical text. Lippincott Williams & Wilkins, Philadelphia

41.

Rizza RA, Cryer PE, Gerich JE (1979) Role of glucagon, catecholamines, and growth hormone in human glucose counterregulation. Effects of somatostatin and combined alpha- and beta-adrenergic blockade on plasma glucose recovery and glucose flux rates after insulin-induced hypoglycemia. J Clin Investig 64:62–71CrossRefPubMedPubMedCentral

42.

Rosen SG, Clutter WE, Berk MA, Shah SD, Cryer PE (1984) Epinephrine supports the postabsorptive plasma glucose concentration and prevents hypoglycemia when glucagon secretion is deficient in man. J Clin Invest 73:405–411CrossRefPubMedPubMedCentral

43.

Elmquist JK, Bjorbaek C, Ahima RS, Flier JS, Saper CB (1998) Distributions of leptin receptor mRNA isoforms in the rat brain. J Comp Neurol 395:535–547CrossRefPubMed

44.

Munzberg H, Flier JS, Bjorbaek C (2004) Region-specific leptin resistance within the hypothalamus of diet-induced obese mice. Endocrinology 145:4880–4889CrossRefPubMed

45.

Haque MS, Minokoshi Y, Hamai M, Iwai M, Horiuchi M, Shimazu T (1999) Role of the sympathetic nervous system and insulin in enhancing glucose uptake in peripheral tissues after intrahypothalamic injection of leptin in rats. Diabetes 48:1706–1712CrossRefPubMed

46.

Minokoshi Y, Haque MS, Shimazu T (1999) Microinjection of leptin into the ventromedial hypothalamus increases glucose uptake in peripheral tissues in rats. Diabetes 48:287–291CrossRefPubMed

47.

Bingham NC, Anderson KK, Reuter AL, Stallings NR, Parker KL (2008) Selective loss of leptin receptors in the ventromedial hypothalamic nucleus results in increased adiposity and a metabolic syndrome. Endocrinology 149:2138–2148CrossRefPubMedPubMedCentral

48.

Dhillon H, Zigman JM, Ye C et al (2006) Leptin directly activates SF1 neurons in the VMH, and this action by leptin is required for normal body-weight homeostasis. Neuron 49:191–203CrossRefPubMed

49.

Nonogaki K, Iguchi A (1997) Role of central neural mechanisms in the regulation of hepatic glucose metabolism. Life Sci 60:797–807CrossRefPubMed

50.

Meek TH, Matsen ME, Dorfman MD et al (2013) Leptin action in the ventromedial hypothalamic nucleus is sufficient, but not necessary, to normalize diabetic hyperglycemia. Endocrinology 154:3067–3076CrossRefPubMedPubMedCentral

51.

da Silva AA, do Carmo JM, Freeman JN, Tallam LS, Hall JE (2009) A functional melanocortin system may be required for chronic CNS-mediated antidiabetic and cardiovascular actions of leptin. Diabetes 58:1749–1756CrossRefPubMedPubMedCentral

52.

Meek TH, Matsen ME, Damian V, Cubelo A, Chua SC Jr, Morton GJ (2014) Role of melanocortin signaling in neuroendocrine and metabolic actions of leptin in male rats with uncontrolled diabetes. Endocrinology 155:4157–4167CrossRefPubMedPubMedCentral

53.

Fujikawa T, Berglund ED, Patel VR et al (2013) Leptin engages a hypothalamic neurocircuitry to permit survival in the absence of insulin. Cell Metab 18:431–444CrossRefPubMedPubMedCentral

54.

Flak JN, Patterson CM, Garfield AS et al (2014) Leptin-inhibited PBN neurons enhance responses to hypoglycemia in negative energy balance. Nat Neurosci 17:1744–1750CrossRefPubMedPubMedCentral

55.

Garfield AS, Shah BP, Madara JC et al (2014) A parabrachial-hypothalamic cholecystokinin neurocircuit controls counterregulatory responses to hypoglycemia. Cell Metab 20:1030–1037CrossRefPubMedPubMedCentral

56.

Carter ME, Soden ME, Zweifel LS, Palmiter RD (2013) Genetic identification of a neural circuit that suppresses appetite. Nature 503:111–114CrossRefPubMedPubMedCentral

57.

Aponte Y, Atasoy D, Sternson SM (2011) AGRP neurons are sufficient to orchestrate feeding behavior rapidly and without training. Nat Neurosci 14:351–355CrossRefPubMedPubMedCentral

58.

Krashes MJ, Koda S, Ye C et al (2011) Rapid, reversible activation of AgRP neurons drives feeding behavior in mice. J Clin Invest 121:1424–1428CrossRefPubMedPubMedCentral

59.

Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM (1994) Positional cloning of the mouse obese gene and its human homologue. Nature 372:425–432CrossRefPubMed

60.

Farr OM, Gavrieli A, Mantzoros CS (2015) Leptin applications in 2015: what have we learned about leptin and obesity? Curr Opin Endocrinol Diabetes Obes 22:353–359CrossRefPubMed

61.

Cummings BP, Bettaieb A, Graham JL et al (2011) Subcutaneous administration of leptin normalizes fasting plasma glucose in obese type 2 diabetic UCD-T2DM rats. Proc Natl Acad Sci U S A 108:14670–14675CrossRefPubMedPubMedCentral

Titel: The role of leptin in diabetes: metabolic effects
verfasst von: Thomas H. Meek
Gregory J. Morton
Publikationsdatum: 11.03.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: Diabetologia / Ausgabe 5/2016
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-016-3898-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

23.04.2024 | Ablationstherapie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

The role of leptin in diabetes: metabolic effects

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Hinter dieser Appendizitis steckte ein Erreger

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2016

Up front May 2016

Methylation of insulin DNA in response to proinflammatory cytokines during the progression of autoimmune diabetes in NOD mice

First-trimester multimarker prediction of gestational diabetes mellitus using targeted mass spectrometry

Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism

Microbial transmission from mothers with obesity or diabetes to infants: an innovative opportunity to interrupt a vicious cycle

Insomnia does not mediate or modify the association between MTNR1B risk variant rs10830963 and glucose levels

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Hinter dieser Appendizitis steckte ein Erreger

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Innere Medizin